Categories: DevelopmentDiagnosticsScienceTechnology
Diagnostic test to predict responders to immunotherapy in case of cancer.
Investors 5
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.03.2021 | - | $14M | - |
| 13.02.2017 | - | $8M | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.06.2022 | Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer | LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient ... |
| 31.03.2021 | Treos Bio Announces $14 Million Convertible Loan Note Financing to Advance Platform of Computationally Designed Peptide-Based Cancer Immunotherapies | Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer
Financing was led by Luminous Ventures and the UK Government’s Future Fund
Isabel Fox, Co-M... |
| 13.02.2017 | Treos Bio Completes $8M in Funding | Treos Bio, Ltd., a London, UK- and Bethesda, MD-based developer of precision cancer immunotherapies paired to companion diagnostics, completed an $8m funding.
The investors were not disclosed.
The company intends to use the funds for the ea... |
| - | Treos Bio | “Treos Bio” |
Reviews 0
